Organovo sells FXR program to Eli Lilly Company

Organovo Holdings, Inc. has completed the sale of its FXR program to Eli Lilly and Company. The announcement came on March 25, 2025. Organovo is a biotechnology company focused on new treatments for inflammatory bowel disease. With this sale, Organovo will receive an upfront payment. It will also earn payments later when key milestones are reached for the lead asset, FXR314. Eli Lilly will gain all rights to develop the FXR program worldwide. They will handle all future clinical developments related to the program. Organovo specializes in creating drugs using their unique technology. This technology builds three-dimensional (3D) human tissues that closely resemble natural human tissues.